Obesity Drug Stocks On Watch Ahead of FDA CV AdCom (VVUS) (OREX) (ARNA)
Tweet
Share
E-mail
Get Alerts VVUS Hot Sheet
Join SI Premium – FREE
Traders have their eyes on obesity drug makers VIVUS, Inc. (Nasdaq: VVUS), Orexigen Therapeutics, Inc. (Nasdaq: OREX) and Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) ahead of this week's AdCom on CV risks related to the drugs.
FDA briefing documents have now been posted for the March 28-29 meeting. You can find them here.
VIVUS has already received FDA panel backing for its Qnexa, which has a PDUFA date of April 17, 2012.
FDA briefing documents have now been posted for the March 28-29 meeting. You can find them here.
VIVUS has already received FDA panel backing for its Qnexa, which has a PDUFA date of April 17, 2012.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nscale targets up to $3B in US IPO as soon as September - Bloomberg
- FTC files amicus brief challenging Amgen's Enbrel patent acquisition
- Uber fined $966 Million in the Netherlands for automating driver suspensions - Reuters
Create E-mail Alert Related Categories
FDA, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
